FDA CDER SSRI Listening Session Minutes, March 24, 2026
Summary
FDA's Center for Drug Evaluation and Research (CDER) convened an SSRI (Selective Serotonin Reuptake Inhibitor) listening session on March 24, 2026, publishing minutes and three related presentations. Topics addressed included a petition for balanced evidence-based pregnancy warnings on serotonergic drugs and methods for safely deprescribing psychiatric medications. The documents were made available via Regulations.gov docket FDA-2025-P-1305-0288.
About this source
Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.
What changed
FDA's CDER convened an SSRI listening session on March 24, 2026, publishing minutes and three presentations as part of docket FDA-2025-P-1305-0288. The attachments include an overview of a petition to require balanced evidence-based pregnancy warnings for serotonergic reuptake inhibitors and a presentation on safe deprescribing of psychiatric drugs.\n\nAffected parties including pharmaceutical manufacturers, healthcare providers, and patients with interest in SSRI labeling and prescribing practices should monitor this docket for further FDA engagement on these topics. The listening session format indicates FDA is actively soliciting stakeholder input on SSRI-related safety communications but does not represent a formal regulatory action or commitment.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
There are no documents available to view or download
Attachments 3
SSRI listening session minutes_3-24-26
More Information
- Author(s) CDER
Download
AbuDagga A. Overview of Petition to Require Balanced Evidence-Based Pregnancy Warnings for SRIs_03.23.2026
More Information
- Author(s) CDER
Download
Horowitz M. How to safely deprescribe psychiatric drugs_03.23.2026
More Information
- Author(s) CDER
Download
Mentioned entities
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.